Atul Dandekar, Chief Strategy and Business Officer of Maze Therapeutics, Inc. (NASDAQ:MAZE), filed a Form 4 on October 30, 2026, reporting transactions in common stock executed on October 29, 2026, pursuant to a Rule 10b5-1 trading plan.

Key Highlights

  • Stock options exercised: Dandekar exercised two stock options on October 29, 2026, acquiring a total of 7,500 shares of common stock at an exercise price of $10.42 per share via transaction code M.
  • Shares sold: 7,500 shares of common stock were disposed of on October 29, 2026, at a weighted average price of $32.0709 per share, with individual transactions ranging from $31.61 to $32.56 per share.
  • Remaining direct ownership: Following the transactions, Dandekar directly beneficially owns 32,316 shares of common stock.
  • Rule 10b5-1 plan: According to the filing, all transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by Dandekar on September 29, 2025.
  • Remaining derivative securities: After the transactions, Dandekar holds 25,073 derivative securities (stock options) directly, with 0 remaining from the fully vested option and 25,073 from the second option.

Dandekar's October 2026 Option Exercise and Sale at Maze Therapeutics

According to the Form 4 filing, Atul Dandekar, identified as CSBO (Chief Strategy and Business Officer) of Maze Therapeutics, Inc., reported two option exercises and one open-market sale of common stock on October 29, 2026. The first exercise converted 6,643 stock options with an exercise price of $10.42 into 6,643 shares of common stock. The second exercise converted 857 stock options at the same $10.42 exercise price into 857 shares. Combined, the two exercises added 7,500 shares to Dandekar's holdings before the reported sale.

Following the exercises, the filing reports that Dandekar sold all 7,500 shares at a weighted average price of $32.0709. The filing notes these shares were sold in multiple transactions at prices ranging from $31.61 to $32.56 per share, inclusive, and that full pricing detail is available upon request to the issuer, any security holder, or SEC staff. After both the acquisitions and the disposal, Dandekar's direct beneficial ownership of common stock stood at 32,316 shares, according to the filing.

Regarding the underlying options, the filing states that the first option, covering 6,643 shares, was fully vested as of March 17, 2025, with an expiration date of April 11, 2031. The second option, covering 857 shares exercised as part of this transaction, vests at 1/48th of the total award monthly, with the first tranche vesting on April 1, 2024, and subsequent tranches vesting on each monthly anniversary. The filing reports 25,073 derivative securities (stock options) remain directly held by Dandekar following these transactions. The form was signed by Courtney Phillips, as attorney-in-fact, on October 30, 2026.

What Was Disclosed

The filing disclosed that Maze Therapeutics CSBO Atul Dandekar exercised stock options for 7,500 shares at $10.42 each and sold those 7,500 shares at a weighted average price of $32.0709 on October 29, 2026, under a pre-established Rule 10b5-1 trading plan, leaving him with 32,316 shares of common stock directly held.